SOUTH SAN FRANCISCO (dpa-AFX) – Genentech, a member of the Roche Group, said it has been made aware of an inadvertent disclosure of the second interim analysis of the Phase III SKYSCRAPER-01 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq versus Tecentriq alone as an initial treatment for people…Read More
Genentech Issues Update On Phase III SKYSCRAPER01 Study
